Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
STAT+: Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
STAT November 11, 2024
Emraclidine was a centerpiece of the company’s purchase of Cerevel Therapeutics
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent...
Today's Sponsors
Today's Sponsor